3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasm Metastasis
3
Multiple Myeloma
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Richter's Transformation
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Liver Neoplasms
1
Glioma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Castration Levels of Testosterone
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Interventions
Docetaxel
56
Prednisone
36
enzalutamide
25
Leuprolide
24
Magnetic Resonance Spectroscopy
19
Abiraterone Acetate
19
bicalutamide
17
Radiotherapy
15
Goserelin
15
abiraterone
12
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
11
olaparib
9
Androgen Antagonists
9
gallium 68 PSMA-11
8
cabazitaxel
8
Radiotherapy, Intensity-Modulated
8
Metformin
8
Ketoconazole
8
Gonadotropin-Releasing Hormone
8
Cyclophosphamide
8
apalutamide
7
Doxorubicin
7
luprolide acetate gel depot
6
cabozantinib
6
Radiosurgery
6
Estramustine
6
Dexamethasone
6
Calcitriol
6
Biopsy
6
pembrolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Prostatic Neoplasms
×
selinexor
×
Clear all
NCT02146833
2023-01-26
SHIP
Karyopharm Therapeutics Inc
Phase 2
Terminated
20 enrolled
13 charts